Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519–530 (2020).
Ma, F. et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ 383, e076065 (2023).
Gion, M. et al. Systemic therapy for HER2-positive metastatic breast cancer: moving into a new era. Am. Soc. Clin. Oncol. Educ. Book 42, 82–92 (2022).
Xu, B. et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res. Treat. 197, 503–513 (2023).
McCullough, A. E. et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res. Treat. 143, 485–492 (2014).
Garrett, J. T. & Arteaga, C. L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11, 793–800 (2011).
Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 351–360 (2021).
De Leon, J. China approves Hengrui breast cancer drug on phase II data. biocentury.com, https://www.biocentury.com/bc-extra/company-news/2018-08-22/china-approves-hengrui-breast-cancer-drug-phase-ii-data (2018).
Scaltriti, M. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803–814 (2009).
Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110–2120 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.C. has received honoraria for speaker’s engagement from Bristol Myers Squibb (BMS), Celltrion, Foundation Medicine, Lilly, MSD, Novartis, Pfizer, NanoString, Roche, Samsung and Seattle Genetics; for consultancy roles from NanoString, Roche and Seattle Genetics; for participating in advisory boards from Celltrion, Foundation Medicine, Lilly, Mylan, Pfizer, Roche and Samsung; for writing engagement from BMS and Novartis; and for participation in the Ellipsis Scientific Affairs Group. G.C. also reports institutional research funding for conducting phase I and II clinical trials from AbbVie, AstraZeneca, Bayer, BMS, Celgene, Janssen-Cilag, Medimmune, Medivation, Merck Serono, MSD, Novartis, Orion, Pfizer, Philogen, Roche, Sanofi, Seattle Genetics, Servier and Tesaro. G.C. also declares non-financial interests with the Italian National Health Council as Advisor for Ministry of Health, the European Society for Medical Oncology (ESMO) as Clinical Practice Guidelines Chair, Europa Donna as Member of the Scientific Council, the European Society of Breast Cancer Specialists (EUSOMA) as a member of the Advisory Council and Fondazione Beretta. All of these competing interests were outside the submitted work. P.P.M.B.G. declares no competing interests.
Rights and permissions
About this article
Cite this article
Berton Giachetti, P.P.M., Curigliano, G. Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?. Nat Rev Clin Oncol 21, 171–172 (2024). https://doi.org/10.1038/s41571-023-00854-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00854-y
